HUE051399T2 - 2-butoxi-7-(4-(pirrolidin-1-ilmetil)benzil)-5H-pirrolo[3,2-D]pirimidin-4-amin a kristályformája mint TLR7 agonista, elõállítási eljárása és alkalmazása - Google Patents
2-butoxi-7-(4-(pirrolidin-1-ilmetil)benzil)-5H-pirrolo[3,2-D]pirimidin-4-amin a kristályformája mint TLR7 agonista, elõállítási eljárása és alkalmazásaInfo
- Publication number
- HUE051399T2 HUE051399T2 HUE17747004A HUE17747004A HUE051399T2 HU E051399 T2 HUE051399 T2 HU E051399T2 HU E17747004 A HUE17747004 A HU E17747004A HU E17747004 A HUE17747004 A HU E17747004A HU E051399 T2 HUE051399 T2 HU E051399T2
- Authority
- HU
- Hungary
- Prior art keywords
- pyrrolo
- pyrrolidin
- pyrimidin
- ylmethyl
- butoxy
- Prior art date
Links
- VMDGIQUJSYPMLF-UHFFFAOYSA-N C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N Chemical compound C(CCC)OC=1N=C(C2=C(N=1)C(=CN2)CC1=CC=C(C=C1)CN1CCCC1)N VMDGIQUJSYPMLF-UHFFFAOYSA-N 0.000 title 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610082029.8A CN107043379A (zh) | 2016-02-05 | 2016-02-05 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE051399T2 true HUE051399T2 (hu) | 2021-03-01 |
Family
ID=59499348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17747004A HUE051399T2 (hu) | 2016-02-05 | 2017-02-04 | 2-butoxi-7-(4-(pirrolidin-1-ilmetil)benzil)-5H-pirrolo[3,2-D]pirimidin-4-amin a kristályformája mint TLR7 agonista, elõállítási eljárása és alkalmazása |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10442811B2 (enExample) |
| EP (1) | EP3412672B1 (enExample) |
| JP (1) | JP6889171B2 (enExample) |
| KR (1) | KR102393280B1 (enExample) |
| CN (2) | CN107043379A (enExample) |
| AR (1) | AR107548A1 (enExample) |
| AU (1) | AU2017215801B2 (enExample) |
| CA (1) | CA3013518C (enExample) |
| CL (1) | CL2018002092A1 (enExample) |
| DK (1) | DK3412672T3 (enExample) |
| EA (1) | EA035951B1 (enExample) |
| ES (1) | ES2830443T3 (enExample) |
| HR (1) | HRP20201644T1 (enExample) |
| HU (1) | HUE051399T2 (enExample) |
| IL (1) | IL260968B (enExample) |
| LT (1) | LT3412672T (enExample) |
| MX (1) | MX374297B (enExample) |
| NZ (1) | NZ744884A (enExample) |
| PH (1) | PH12018501643A1 (enExample) |
| PL (1) | PL3412672T3 (enExample) |
| PT (1) | PT3412672T (enExample) |
| SG (1) | SG11201806683UA (enExample) |
| SI (1) | SI3412672T1 (enExample) |
| TW (1) | TWI754629B (enExample) |
| UA (1) | UA121161C2 (enExample) |
| WO (1) | WO2017133684A1 (enExample) |
| ZA (1) | ZA201805186B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043378A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体 |
| EP3816166A4 (en) * | 2018-05-25 | 2022-04-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Tlr7 agonist and pharmaceutical combination thereof for treating lung cancer |
| WO2020162705A1 (ko) | 2019-02-08 | 2020-08-13 | 성균관대학교산학협력단 | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 |
| EP3937944A1 (en) * | 2019-03-15 | 2022-01-19 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | Toll-like receptor agonists for use in the treatment of hepatitis b |
| SG11202111488YA (en) * | 2019-04-23 | 2021-11-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Solid pharmaceutical composition comprising tlr7 agonist |
| US20230100429A1 (en) | 2020-03-02 | 2023-03-30 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| JP7690222B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン |
| CN116056725A (zh) | 2020-08-04 | 2023-05-02 | 蛋白科技先鋒 | 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途 |
| EP4194008A4 (en) | 2020-08-04 | 2025-01-08 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| CN119431359A (zh) * | 2023-07-28 | 2025-02-14 | 苏州申拓医药科技有限公司 | 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3376479B2 (ja) * | 1991-08-12 | 2003-02-10 | 武田薬品工業株式会社 | 縮合ピリミジン誘導体、その製造法および用途 |
| CN101304748A (zh) * | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
| CN103497192B (zh) | 2008-12-09 | 2015-09-23 | 吉里德科学公司 | Toll样受体调节剂 |
| EP2670244B1 (en) * | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| WO2013103967A1 (en) * | 2012-01-05 | 2013-07-11 | Northeastern University | Allosteric modulators of cb1 cannabinoid receptors |
| MX386924B (es) | 2012-10-10 | 2025-03-19 | Janssen Sciences Ireland Uc | Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades. |
| EP2922547B1 (en) | 2012-11-20 | 2017-03-08 | Glaxosmithkline LLC | Novel compounds |
| AU2013348217B2 (en) * | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
| SMT201700378T1 (it) * | 2012-11-20 | 2017-09-07 | Glaxosmithkline Llc | Nuovi composti |
| EA030603B1 (ru) * | 2014-05-01 | 2018-08-31 | Новартис Аг | СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ АГОНИСТОВ Toll-ПОДОБНОГО РЕЦЕПТОРА 7 |
| EA032824B1 (ru) | 2014-08-15 | 2019-07-31 | Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд. | Пирролопиримидиновые соединения, используемые в качестве агониста tlr7 |
| CN105367576A (zh) | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| CN107043379A (zh) * | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的晶型a、其制备方法和医药用途 |
| CN107043380A (zh) | 2016-02-05 | 2017-08-15 | 正大天晴药业集团股份有限公司 | 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途 |
-
2016
- 2016-02-05 CN CN201610082029.8A patent/CN107043379A/zh active Pending
-
2017
- 2017-02-03 TW TW106103695A patent/TWI754629B/zh active
- 2017-02-04 SI SI201730461T patent/SI3412672T1/sl unknown
- 2017-02-04 EP EP17747004.4A patent/EP3412672B1/en active Active
- 2017-02-04 ES ES17747004T patent/ES2830443T3/es active Active
- 2017-02-04 PL PL17747004T patent/PL3412672T3/pl unknown
- 2017-02-04 HR HRP20201644TT patent/HRP20201644T1/hr unknown
- 2017-02-04 PT PT177470044T patent/PT3412672T/pt unknown
- 2017-02-04 CA CA3013518A patent/CA3013518C/en active Active
- 2017-02-04 KR KR1020187024627A patent/KR102393280B1/ko active Active
- 2017-02-04 SG SG11201806683UA patent/SG11201806683UA/en unknown
- 2017-02-04 DK DK17747004.4T patent/DK3412672T3/da active
- 2017-02-04 LT LTEP17747004.4T patent/LT3412672T/lt unknown
- 2017-02-04 MX MX2018009501A patent/MX374297B/es active IP Right Grant
- 2017-02-04 US US16/075,297 patent/US10442811B2/en active Active
- 2017-02-04 UA UAA201809129A patent/UA121161C2/uk unknown
- 2017-02-04 EA EA201891768A patent/EA035951B1/ru not_active IP Right Cessation
- 2017-02-04 AU AU2017215801A patent/AU2017215801B2/en active Active
- 2017-02-04 NZ NZ744884A patent/NZ744884A/en unknown
- 2017-02-04 CN CN201780009747.5A patent/CN108602831B9/zh active Active
- 2017-02-04 WO PCT/CN2017/072891 patent/WO2017133684A1/zh not_active Ceased
- 2017-02-04 HU HUE17747004A patent/HUE051399T2/hu unknown
- 2017-02-04 JP JP2018540799A patent/JP6889171B2/ja active Active
- 2017-02-06 AR ARP170100297A patent/AR107548A1/es not_active Application Discontinuation
-
2018
- 2018-08-01 ZA ZA2018/05186A patent/ZA201805186B/en unknown
- 2018-08-02 IL IL260968A patent/IL260968B/en unknown
- 2018-08-02 PH PH12018501643A patent/PH12018501643A1/en unknown
- 2018-08-03 CL CL2018002092A patent/CL2018002092A1/es unknown
-
2019
- 2019-09-25 US US16/582,575 patent/US10947245B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE051399T2 (hu) | 2-butoxi-7-(4-(pirrolidin-1-ilmetil)benzil)-5H-pirrolo[3,2-D]pirimidin-4-amin a kristályformája mint TLR7 agonista, elõállítási eljárása és alkalmazása | |
| HUE043122T2 (hu) | Pirazolo[1,5-a]pirimidin-5,7-diamin vegyületek mint CDK inhibitorok és terápiás alkalmazásuk | |
| KR102637617B9 (ko) | 극도로 내구성이 우수한 리튬 인터칼레이션을 나타내는 신규 물질 및 그의 제조 방법 | |
| IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
| LT3429591T (lt) | Pakeistojo tieno[2,3-d]pirimidino dariniai kaip menino-mll inhibitoriai ir jų panaudojimo būdai | |
| DK3699181T3 (da) | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat | |
| EP2998389A4 (en) | PRODUCTION PROCESS FOR SHEET CELL CULTURE | |
| LT3102609T (lt) | Gamybos būdas autologinių t ląstelių, naudotinų b ląstelių piktybinių navikų ir kitų vėžio rūšių gydymui, bei jų kompozicijos | |
| ZA201805240B (en) | Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses | |
| MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| EP3096763A4 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
| IL253360A0 (en) | New crystalline forms of neratinib malate and a process for their preparation | |
| HUE040304T2 (hu) | 2-Amino-6-(difluor-metil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridinek, mint bace1 inhibitorok | |
| PL3487861T3 (pl) | Sole kwasu diorganylofosfinowego, sposób ich wytwarzania i ich zastosowanie | |
| PT3114126T (pt) | Derivados de 1,2-dihidro-3h pirrolo[1,2-c]imidazol-3-ona e a sua utilização como agentes antibacterianos | |
| HUE052211T2 (hu) | TLR7 agonista maleát-só, annak C,D és E kristályos formái, és a maleátsó és a kristályos formák elõállítási eljárásai és alkalmazásai | |
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| HUE053455T2 (hu) | Eljárás pirrolo[3,2-D]pirimidin vegyület elõállítására és intermedierjei | |
| MX2017001487A (es) | Sofosbuvir en forma cristalina y proceso para su preparacion. | |
| EP3378466A4 (en) | COMPOSITION FOR USE IN ORAL CAVITY | |
| EP3196199A4 (en) | Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor | |
| ZA202401526B (en) | 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2- (homo)piperazine 1,3-benzothiazine-4-one hydrochlorides | |
| EP3040337A4 (en) | 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof | |
| GB2559718B (en) | Novel crystalline form of tribenuron-methyl, process for preparation and use thereof | |
| EP3505508A4 (en) | COMPOSITION FOR USE IN THE DETECTION OF AN ALLERGY ON CLAVULANIC ACID |